Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIVA-SVT Pilot
NCT06965998Phase 3Recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in superficial vein thrombosis (SVT) comparing Full Dose Rivaroxaban with Low Dose Rivaroxaban / Placebo (2 arms). Primary endpoint: Primary Feasibility Outcome at 12 months. Started Aug 2025; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
superficial vein thrombosis (SVT)
Beyond the preview
Go deeper on NCT06965998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06965998.